Adn432: New

Why are laboratories rushing to replace their old stocks with ADN432 new? The standout features include:

Researchers at the Institute of Molecular Neuroscience have used ADN432 new to silence mutant huntingtin protein (mHTT) in patient-derived induced pluripotent stem cells (iPSCs). Early data suggest that a single 100 nM treatment achieves 70% knockdown without detectable cytotoxicity—a major improvement over previous ASOs.

| Parameter | Value | | :--- | :--- | | Interface Type | RS-485 / RS-422 | | Duplex Mode | Half-Duplex | | Data Rate | Up to 20 Mbps | | Supply Voltage | 3.0V to 5.5V | | Operating Temp | −40°C to +85°C | | ESD Protection | ±15kV (HBM) on Bus Pins | | Package | 8-Lead SOIC_N | adn432 new

For the first time in the ADN432 line, the ADN432 New is available in a lyophilized bead format. This is ideal for field diagnostics and point-of-care (POC) applications where cold chain logistics are unreliable.

3.1 Inclusions (In-Scope)

3.2 Exclusions (Out-of-Scope)

| Patent | Scope | Expiry | |--------|-------|--------| | US 10,845,321 – Core peptide sequence & cyclization methodology | US, Canada, EU, JP, AU | 2037 | | US 11,012,004 – Oral formulation & enteric coating | US, EU, CN | 2039 | | WO 2023/125678 – Combination therapy with β‑lactamase inhibitor | World (PCT) | 2035 | | US 2026/018934 – Manufacturing process (continuous SPPS) | US, EU | 2042 | Why are laboratories rushing to replace their old

Freedom‑to‑operate analysis (2025) shows no material infringement risk from existing AMPs or small‑molecule antibiotics.